Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

September 22, 2027

Study Completion Date

September 22, 2027

Conditions

Melanoma

Interventions

DRUG

tunlametinib

12mg BID

DRUG

paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin

according to investigators' suggestion

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT06008106 - Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | Biotech Hunter | Biotech Hunter